arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Equillium, Inc.

EQ
$2.11 ▼ -0.01 (-0.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Equillium, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $203.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -7.5%
FCF / Share $-0.04
Trailing P/E
Price / Book 2.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.39M
↓ -52.3%
Net Income Profit after all expenses
$-5.31M
↑ +38.6%
Operating Margin Operating profit as % of sales
-107.0%
↓ -1815.8%
FCF / Share Free cash flow per share
$-0.04
↑ +80.5%
Long-Term Debt Long-term obligations
$7.64M
↓ -26.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 36 quarters